Subscribe
dna-istock-518143098-ralwel--2
ralwel / iStockphoto.com
22 March 2018Europe

LSIPR Webinar: Greater scrutiny for late-filed EPO documents, says HGF

Late-filed documents will come under greater scrutiny in light of changes to the European Patent Office’s (EPO) opposition procedure.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
LSIPR webinar: HGF on doctrine of equivalence evolution
16 October 2018   The case of Actavis v Eli Lilly introduced “a real change in the law” and the way in which it addresses the doctrine of equivalence, according to Douglas Drysdale, partner at HGF in Glasgow, UK.
Big Pharma
LSIPR webinar: HGF delves into personalised healthcare patents
13 September 2018   Personalised healthcare is a rapidly developing field, not just because of medical advancements, but also because the criteria necessary to secure second medical use patents has similarly evolved over the years, an industry webinar heard.
Americas
LSIPR webinar: BSKB dissects antibody patents
1 February 2018   When it comes to patenting antibodies, “written description seems to be the big issue these days”, according to Gerald Murphy, IP partner at law firm Birch Stewart Kolasch Birch.


Editor's picks

‘We created law’: G1/24 and the creation of the ‘diamond standard’
Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025

Editor's picks

Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025

More on this story

Big Pharma
LSIPR webinar: HGF on doctrine of equivalence evolution
16 October 2018   The case of Actavis v Eli Lilly introduced “a real change in the law” and the way in which it addresses the doctrine of equivalence, according to Douglas Drysdale, partner at HGF in Glasgow, UK.
Big Pharma
LSIPR webinar: HGF delves into personalised healthcare patents
13 September 2018   Personalised healthcare is a rapidly developing field, not just because of medical advancements, but also because the criteria necessary to secure second medical use patents has similarly evolved over the years, an industry webinar heard.
Americas
LSIPR webinar: BSKB dissects antibody patents
1 February 2018   When it comes to patenting antibodies, “written description seems to be the big issue these days”, according to Gerald Murphy, IP partner at law firm Birch Stewart Kolasch Birch.

More on this story

Big Pharma
LSIPR webinar: HGF on doctrine of equivalence evolution
16 October 2018   The case of Actavis v Eli Lilly introduced “a real change in the law” and the way in which it addresses the doctrine of equivalence, according to Douglas Drysdale, partner at HGF in Glasgow, UK.
Big Pharma
LSIPR webinar: HGF delves into personalised healthcare patents
13 September 2018   Personalised healthcare is a rapidly developing field, not just because of medical advancements, but also because the criteria necessary to secure second medical use patents has similarly evolved over the years, an industry webinar heard.
Americas
LSIPR webinar: BSKB dissects antibody patents
1 February 2018   When it comes to patenting antibodies, “written description seems to be the big issue these days”, according to Gerald Murphy, IP partner at law firm Birch Stewart Kolasch Birch.

More features

‘We created law’: G1/24 and the creation of the ‘diamond standard’
BMS unit loses cell therapy patent at European Patent Office
Amgen sues Biocon over blockbuster bone drugs as first biosimilars enter market
Lord Justice Birss to become chancellor of the High Court
Bankruptcy judge approves $305m sale of genetics testing company
Sanofi successfully challenges rare disease patent in Europe
Bayer appoints new head of IP
WATCH: Policy direction—where are we now?